Gap Pharm-601: We need to characterize the extent to which spaceflight alters pharmacokinetics and pharmacodynamics.
Last Published:  07/30/21 01:05:31 PM (Central)
Responsible Element: Exploration Medical Capability (ExMC)
Status: Open
Description

State of Knowledge: Pharmacokinetics (PK) is the study of how the body handles administered medications which determines the concentration of circulating medication that is available to act upon the body. Understanding PK is critical to accurate dosing, but the effects of the spaceflight environment on PK are not well understood. 

Pharmacodynamics (PD) is the study of how administered medications interact with their physiological targets which determines the actions of circulating medications on the body. Understanding PD is critical to appropriate treatment, but the effects of the spaceflight environment on PD are not well understood. 


Existing PK/PD models have not been validated for the spaceflight environment and astronaut data with respect to PK/PD are too sparse to permit conclusions.


Approach: TBD
Target for Closure
TBD
Mappings
Risk Risk of Ineffective or Toxic Medications During Long-Duration Exploration Spaceflight
You are here! Gap Pharm-601: We need to characterize the extent to which spaceflight alters pharmacokinetics and pharmacodynamics.

Multi-Disciplinary Research Plans

Documentation:
No Documentation Available